Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Artiva Biotherapeutics to related companies based on the strength of its risk, profitability, earnings, institutional ownership, dividends, analyst recommendations and valuation.
Earnings & Valuation
This table compares Artiva Biotherapeutics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Artiva Biotherapeutics | $250,000.00 | -$83.86 million | -1.27 |
| Artiva Biotherapeutics Competitors | $730.63 million | $9.19 million | -17.98 |
Artiva Biotherapeutics’ peers have higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Artiva Biotherapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artiva Biotherapeutics | N/A | -45.32% | -41.38% |
| Artiva Biotherapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Risk & Volatility
Artiva Biotherapeutics has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics’ peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Artiva Biotherapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artiva Biotherapeutics | 1 | 4 | 2 | 0 | 2.14 |
| Artiva Biotherapeutics Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Artiva Biotherapeutics currently has a consensus target price of $24.80, suggesting a potential upside of 555.22%. As a group, “Biotechnology” companies have a potential upside of 114.58%. Given Artiva Biotherapeutics’ higher possible upside, equities analysts plainly believe Artiva Biotherapeutics is more favorable than its peers.
Insider & Institutional Ownership
47.8% of shares of all “Biotechnology” companies are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Artiva Biotherapeutics peers beat Artiva Biotherapeutics on 8 of the 13 factors compared.
About Artiva Biotherapeutics
Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company’s lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
